These results demonstrate that CXCR2+ MDSCs can accelerate breast tumor growth and metastasis via directly inducing cancer cells EMT and indirectly promoting T cells exhaustion, suggesting that CXCR2+ MDSCs may be a potential target for breast cancer therapy. This evidence concerns the gene CXCR2 and breast carcinoma.